Patents by Inventor Benedicte Guilbert
Benedicte Guilbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130064770Abstract: The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.Type: ApplicationFiled: May 26, 2011Publication date: March 14, 2013Applicant: GE HEALTHCARE LIMITEDInventors: Ian Martin Newington, Duncan George Wynn, Robert James Domett Nairne, Benedicte Guilbert, Subrata Mandal, Jinto Jose, Sunderaraman Varadarajan, Chitralekha Rangaswamy, Helen Betts, Rebecca Davis
-
Publication number: 20110268660Abstract: The present invention provides a method of imaging useful in the determination of sites of dysplasia in patients suffering from Barrett's oesophagus. The method comprises the use of an optical imaging agent comprising a vector which targets the extracellular domain of EGFR, the vector also being selective for EGFR over Her2. The vector is labelled with an optical reporter suitable for in vivo imaging using light in the green to near-infrared wavelength 500-1200 nm. Also provided are novel optical imaging agents suitable for use in the method.Type: ApplicationFiled: August 14, 2009Publication date: November 3, 2011Inventors: Antonios Danikas, Benedicte Guilbert
-
Publication number: 20110129419Abstract: The present invention relates to the field of medical imaging, and in particular to imaging of disease states associated with the upregulation of the chemokine receptor 5 (CCR5). Imaging agents, precursors and methods are provided which are useful in imaging such disease states.Type: ApplicationFiled: December 19, 2007Publication date: June 2, 2011Applicants: GE HEALTHCARE LIMITED, HAMMERSMITH IMANET LIMITEDInventors: Anthony Eamon Storey, Julie Davis, Erik Arstad, Benedicte Guilbert, Alessandra Gaeta
-
Publication number: 20080286201Abstract: The present invention relates to diagnostic imaging agents for in vivo imaging. The imaging agents comprise a synthetic caspase-3 substrate peptide labelled with an imaging moiety suitable for diagnostic imaging in vivo. The invention also provides radiopharmaceutical compositions comprising the imaging agents, together with kits for the preparation of the radiopharmaceuticals. Also described are non-radioactive precursors suitable for the preparation of the imaging agents. The imaging agents are useful for the diagnostic imaging and or therapy monitoring in vivo of various disease states where caspase-3 is involved.Type: ApplicationFiled: February 3, 2006Publication date: November 20, 2008Inventors: Benedicte Guilbert, Sue Champion, Alexander Mark Gibson, Sally-Anne Ricketts, Michelle Avory, Bente E. Arbo
-
Publication number: 20080279765Abstract: The present invention provides a novel imaging agent targeting the mannose-6-phosphate (M6P) receptor suitable for the non-invasive visualization of fibrosis. A method for the preparation of the imaging agent is also provided by the invention, as well as a precursor for use in said method. The invention also provides a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical composition. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition in which the mannose-6-phosphate receptor is upregulated is provided.Type: ApplicationFiled: December 7, 2006Publication date: November 13, 2008Inventors: Salah Chettibi, Ben Newton, Benedicte Guilbert, Helge Tolleshaug, Magne Solbakken
-
Publication number: 20060292075Abstract: Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for the diagnosis of thrombosis, embolism, atherosclerosis, inflammation or cancer.Type: ApplicationFiled: April 24, 2006Publication date: December 28, 2006Inventors: Anthony Storey, Marivi Mendizabal, Susan Champion, Alex Gibson, Benedicte Guilbert, Ian Wilson, Peter Knox
-
Publication number: 20060275215Abstract: The present invention relates to diagnostic imaging agents for in vivo imaging. The imaging agents comprise a synthetic caspase-3 inhibitor labelled with an imaging moiety suitable for diagnostic imaging in vivo. The invention also provides pharmaceutical and radiopharmaceutical compositions comprising the imaging agents, together with kits for the preparation of the radiopharmaceuticals. Also described are chelator conjugates of the caspase-3 inhibitor, which are suitable for the preparation of imaging agents comprising a radioactive or paramagnetic metal ion. The imaging agents are useful for the diagnostic imaging and or therapy monitoring in vivo of various disease states where caspase-3 is involved.Type: ApplicationFiled: November 26, 2004Publication date: December 7, 2006Inventors: Duncan Hiscock, Ben Newton, Benedicte Guilbert
-
Publication number: 20060120956Abstract: The present invention relates to diagnostic imaging agents for in vivo imaging. The imaging agents comprise a synthetic barbituric acid derivative labelled at the 5-position with an imaging moiety suitable for diagnostic imaging in vivo. The invention also provides pharmaceutical and radiopharmaceutical compositions comprising the imaging agents, together with kits of the preparation of the radiopharmaceuticals. Also described are chelator conjugates of the barbituric acid derivative, which are suitable for the preparation of imaging agents comprising a radioactive or paramagnetic metal ion. The imaging agents are useful for the diagnostic imaging in vivo of various disease states, including atherosclerosis.Type: ApplicationFiled: October 8, 2003Publication date: June 8, 2006Inventors: Klaus Kopka, Hans-Jorg Breyholz, Stefan Wagner, Michael Shafers, Bodo Leykau, Benedicte Guilbert, Duncan Wynn
-
Patent number: 7049289Abstract: Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for the diagnosis of thrombosis, embolism, atherosclerosis, inflammation or cancer.Type: GrantFiled: May 14, 1999Date of Patent: May 23, 2006Assignee: Amersham PLCInventors: Anthony Eamon Storey, Marivi Mendizabal, Susan Champion, Alex Gibson, Benedicte Guilbert, Ian Andrew Wilson, Peter Knox
-
Patent number: 6897209Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula (Y)m-A-NHR)k can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.Type: GrantFiled: August 22, 2003Date of Patent: May 24, 2005Assignee: GE Healthcare LimitedInventors: Alan Michael Forster, Peter Knox, Marivi Mendizabal, Timothy Charles Richardson, Anthony Eamon Storey, Ian Andrew Wilson, Susan Champion, Alex Gibson, Benedicte Guilbert
-
Publication number: 20040076580Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula (Y)m—A—NHR)k can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.Type: ApplicationFiled: August 22, 2003Publication date: April 22, 2004Applicant: AMERSHAM PLCInventors: Alan Michael Forster, Peter Knox, Marivi Mendizabal, Timothy Charles Richardson, Anthony Eamon Storey, Ian Andrew Wilson, Susan Champion, Alex Gibson, Benedicte Guilbert
-
Patent number: 6653299Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula —(Y)m—A—NHR, can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.Type: GrantFiled: October 4, 1999Date of Patent: November 25, 2003Assignee: Nycomed Amersham PLCInventors: Alan Michael Forster, Peter Knox, Marivi Mendizabal, Timothy Charles Richardson, Anthony Eamon Storey, Ian Andrew Wilson, Susan Champion, Alex Gibson, Benedicte Guilbert
-
Patent number: 5874548Abstract: A direct method is disclosed for the regioselective sulfation of an organic molecule having optionally derivatized hydroxyl groups on at least two adjacent carbon atoms. The method comprises the treatment of a di-(optionally substituted alkyl and/or aryl) stannylene acetal derivative of the molecule with an electrophilic sulfating agent, preferably sulfur trioxide/trimethylamine. The disclosed method is useful for the selective sulfation of a variety of mono-, di- and oligosaccharides. Novel saccharides prepared according to this method are also disclosed.Type: GrantFiled: May 16, 1997Date of Patent: February 23, 1999Assignee: Genzyme CorporationInventors: Sabine Flitsch, Benedicte Guilbert
-
Patent number: 5627271Abstract: A process for preparing a glycolipid of formula (I): [(sac).sub.m+n ]--O--CH.sub.2 --CHX--CH(OQ)--Y wherein Q is H or a blocking group; X is N.sub.3 or NH.sub.2 ; Y is a lipid residue; each sac is a saccharide; and m and n are each integers; comprises reacting a corresponding glycolipid of formula (II): (sac).sub.n --O--CH.sub.2 --CHX--CH(OQ)--Y with the corresponding saccharide (sac).sub.m or a reactive derivative thereof, in the presence of an enzyme that catalyses the reaction. Compounds of formulae (I) and (II) are suitable for elaboration to a variety of saccharide ceramides.Type: GrantFiled: October 13, 1994Date of Patent: May 6, 1997Assignee: Genzyme LimitedInventors: Sabine L. Flitsch, Benedicte Guilbert